Amicus Therapeutics Inc (FOLD) EPS is poised to hit 0.07 next quarter: How Investors Can Make It Count the Most?

Zack King

As on Wednesday, Amicus Therapeutics Inc (NASDAQ: FOLD) got off with the flyer as it spiked 1.46% to $9.73, before settling in for the price of $9.59 at the close. Taking a more long-term approach, FOLD posted a 52-week range of $5.51-$10.35.

In the past 5-years timespan, the Healthcare sector firm’s annual sales growth was 34.10%. Meanwhile, its Annual Earning per share during the time was 34.10%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 89.68%. This publicly-traded company’s shares outstanding now amounts to $308.50 million, simultaneously with a float of $301.65 million. The organization now has a market capitalization sitting at $3.00 billion. At the time of writing, stock’s 50-day Moving Average stood at $8.55, while the 200-day Moving Average is $7.58.

Amicus Therapeutics Inc (FOLD) Ownership Facts and Figures

Another important factor to analyze is how key investors are playing towards the stock of the Biotechnology industry. Amicus Therapeutics Inc’s current insider ownership accounts for 2.23%, in contrast to 101.03% institutional ownership. According to the most recent insider trade that took place on Nov 04 ’25, this organization’s Chief People Officer sold 25,643 shares at the rate of 9.51, making the entire transaction reach 243,860 in total value, affecting insider ownership by 322,618.

Amicus Therapeutics Inc (FOLD) Earnings and Revenue Records

Amicus Therapeutics Inc’s EPS increase for this current 12-month fiscal period is 89.68% and is forecasted to reach 0.27 in the upcoming year.

Amicus Therapeutics Inc (NASDAQ: FOLD) Trading Performance Indicators

Let’s observe the current performance indicators for Amicus Therapeutics Inc (FOLD). It’s Quick Ratio in the last reported quarter now stands at 2.09. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 5.01. Similarly, its price to free cash flow for trailing twelve months is now 309.81.

In the same vein, FOLD’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.04, a figure that is expected to reach 0.07 in the next quarter, and analysts are predicting that it will be 0.27 at the market close of one year from today.

Technical Analysis of Amicus Therapeutics Inc (FOLD)

Through scrutinizing the latest numbers posted by the [Amicus Therapeutics Inc, FOLD], it can be observed that its last 5-days Average volume of 4.13 million was lower the volume of 4.19 million, it posted the year before. During the previous 9 days, stock’s Stochastic %D was recorded 88.84% While, its Average True Range was 75.96.

Raw Stochastic average of Amicus Therapeutics Inc (FOLD) in the period of the previous 100 days is set at 98.91%, which indicates a major rise in contrast to 96.10% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 0.37 that was higher than 0.30 volatility it exhibited in the past 100-days period.

News Daemon
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.